White Paper: Anatomy of a failure to launch: A review of barriers to generic and biosimilar market entry and the use of competition law as a remedy

Second wave pandemic preparedness: procurement principles

Policy Roadmap for Medicines Manufacturing Leadership

Call for tenders SANTE/2020/C3/29 for the supply of medicinal products used for intensive care patients subject to the novel coronavirus (COVID-19) disease – policy and technical concerns

COVID-19 “Round 2” – Findings & way forward (Kearney)

Preparing for a potential second COVID-19 wave. Joint statement by Medicines for Europe and EFPIA with Kearney


Quotes from 3rd VAM conference

Christoph Stoller

Physicians recognised potential of Value Added Medicines

Questions and answers on regulatory expectations for medicinal products for human use during the COVID-19 pandemic